STOCK TITAN

GeneDx Holdings Corp. - WGS STOCK NEWS

Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.

GeneDx Holdings Corp. (Nasdaq: WGS) is a leading company in the field of personalized genetic insights, aiming to revolutionize healthcare through genomic and clinical data. The company focuses on providing actionable health insights that help in accurate diagnosis, targeted treatment, and drug discovery. GeneDx is driven by its comprehensive data sets on rare diseases, enabling precision medicine to become a standard practice.

GeneDx operates primarily through two segments: GeneDx, which is the main revenue generator, and Legacy Sema4 diagnostics. The company is well-regarded for its exome and genome testing and has one of the world's most extensive rare disease datasets. Recent achievements include groundbreaking research on exome sequencing for epilepsy patients, which has shown superior clinical outcomes compared to multi-gene panels.

In the fourth quarter of 2023, GeneDx reported strong financial performance, with a significant increase in utilization of exome and genome products, higher reimbursement rates, and reduced cash burn. The company aims to achieve profitability by 2025. GeneDx continues to forge valuable partnerships, such as its collaboration with Komodo Health, to advance drug discovery and patient care.

GeneDx is also making strides in expanding access to its rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs) through a new collaboration with Epic. This integration will allow seamless data sharing between health systems and improve patient outcomes by speeding up the diagnosis and treatment process.

The company's participation in events like the World Orphan Drug Congress highlights its commitment to advancing precision medicine. With a focus on both clinical and biopharma partnerships, GeneDx is well-positioned to continue its growth and impact on the healthcare industry.

For more information, visit the GeneDx website and connect with them on social media platforms like LinkedIn, Facebook, and Instagram.

Rhea-AI Summary

GeneDx (Nasdaq: WGS) will report its financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. A conference call to discuss these results will be held at 4:30 p.m. Eastern Time on the same day. Investors can register to listen to the call online, and a live and archived webcast will be available on the GeneDx investor relations website. GeneDx specializes in genomic insights, offering exome and genome tests to enhance personalized health care and drug discovery. For more information, visit genedx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
conferences earnings
-
Rhea-AI Summary

GeneDx (Nasdaq: WGS) has announced a collaboration with Epic to expand access to rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs). This integration will streamline access for health systems using Epic's electronic health records, improving provider and patient experiences. GeneDx aims to accelerate the adoption of rWGS services, which have seen an 80% year-over-year increase. The company highlights that 11 states now offer Medicaid coverage for rWGS, alongside growing commercial payor support. The collaboration will allow seamless integration of rWGS results into comprehensive medical records, enhancing patient care. GeneDx is also involved in the SeqFirst study at the University of Washington, investigating the impact of broad access to rWGS. The study aims to improve timely and effective treatments for critically ill infants. With over 600,000 exomes and genomes sequenced, GeneDx continues to lead in genomic insights, aiming to deliver better health outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
-
Rhea-AI Summary

GeneDx (Nasdaq: WGS) has announced a new patient access program to increase accessibility to exome sequencing for pediatric epilepsy patients. The program, developed with biopharma partners, aims to provide equitable care and overcome cost barriers for genetic testing. Exome testing, recommended as a first-line test by the National Society of Genetic Counselors and endorsed by the American Epilepsy Society, offers a nearly 25% diagnostic rate for epilepsy, higher than traditional multi-gene panels. Research indicates that genetic diagnoses can lead to up to 90% seizure reduction in some cases. The program will launch to select providers today, with full availability in July.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.2%
Tags
none
Rhea-AI Summary

GeneDx (Nasdaq: WGS) announced its participation in two upcoming investor conferences in June 2024. The company will present at the Jefferies Healthcare Conference in New York City on June 5 at 9:00 a.m. ET and at the 44th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on June 10 at 3:20 p.m. ET. Live and archived webcasts of the presentations will be accessible on the GeneDx investor relations website. GeneDx focuses on delivering improved health outcomes through genomic insights and offers exome and genome tests to provide personalized health plans, accelerate drug discovery, and enhance health system efficiencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences
-
Rhea-AI Summary

GeneDx Holdings Corp. (Nasdaq: WGS) reported first quarter 2024 revenue of $61.5M with 96% year-over-year growth in exome and genome test revenue. Expanded adjusted gross margins to 61%, narrowed adjusted net loss to $8.5M, and raised guidance to $235-$245M for FY 2024 revenue. GeneDx aims for profitability in 2025, showcasing a strong performance and strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.18%
Tags
-
Rhea-AI Summary
GeneDx partners with Komodo Health to expand access to rare disease data set, offering genetic insights for drug pipelines and clinical trials. The partnership aims to accelerate precision medicine and enable personalized treatments for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.5%
Tags
partnership
Rhea-AI Summary
GeneDx (WGS) to Release First Quarter 2024 Financial Results on April 29, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences earnings
-
Rhea-AI Summary
GeneDx (Nasdaq: WGS) showcased its leadership in genomics at the 2024 ACMG Annual Clinical Genetics Meeting, presenting data on exome sequencing superiority over chromosomal microarray, a statistical approach for variant impact prediction, and efforts to democratize genetic testing access. The company aims to revolutionize healthcare by improving diagnostic precision and operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
conferences
-
Rhea-AI Summary
GeneDx (WGS) to Participate in Cowen Healthcare Conference, Hosting Fireside Chat on March 6, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
Rhea-AI Summary
GeneDx Holdings Corp. (WGS) reported strong fourth quarter 2023 financial results with revenue of $58.1M, 68% growth in exome and genome test revenue, and adjusted gross margins of 56%. The company narrowed its adjusted net loss to $17.8M and reduced cash burn by 51% year-over-year. GeneDx issued guidance for FY 2024 revenue between $220M and $230M and aims for profitability in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.63%
Tags

FAQ

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. provides personalized genetic insights to help diagnose, treat, and improve drug discovery through exome and genome testing.

What are GeneDx's main business segments?

GeneDx operates through two main segments: the GeneDx unit, which generates most of the revenue, and the Legacy Sema4 diagnostics unit.

What recent achievements has GeneDx made?

GeneDx recently published research showing the effectiveness of exome sequencing for epilepsy patients and reported strong financial performance for Q4 2023.

What partnerships does GeneDx have?

GeneDx has collaborated with Komodo Health to advance drug discovery and with Epic to expand its rapid whole genome sequencing services in NICUs.

What is the significance of GeneDx's exome and genome testing?

GeneDx's exome and genome testing help in accurate diagnosis, targeted treatment, and improved drug discovery, especially for rare diseases.

How is GeneDx impacting neonatal care?

GeneDx's collaboration with Epic enables rapid whole genome sequencing in NICUs, improving the diagnosis and treatment of critically ill infants.

When does GeneDx expect to achieve profitability?

GeneDx aims to reach profitability by 2025, supported by increased product utilization and higher reimbursement rates.

How extensive is GeneDx's rare disease data set?

GeneDx possesses one of the world's largest rare disease data sets, which is key to its precision medicine initiatives.

What events does GeneDx participate in?

GeneDx participates in events like the World Orphan Drug Congress to discuss advancements in precision medicine.

Where can I find more information about GeneDx?

You can visit the GeneDx website at www.genedx.com and follow them on LinkedIn, Facebook, and Instagram for the latest updates.

GeneDx Holdings Corp.

Nasdaq:WGS

WGS Rankings

WGS Stock Data

875.79M
26.15M
31.42%
55.98%
4.3%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States of America
STAMFORD